The United Kingdom and the United States have announced a major trade agreement that will ensure zero tariffs on UK medicine shipments being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to increase spending on medicines through the National Health Service (NHS). This commitment secures that tariffs on these crucial goods will stay at nothing for a period of the next three years.
This development comes after recent warnings to significantly raise duties on branded drug products, with figures mentioned reaching 100%.
"This arrangement between the UK bolsters the global environment for new treatments and brings long-overdue equity to transatlantic drug exports," an announcement declared.
Economic Significance
Medicines represent one of the Britain's most significant export categories to the America, which is easily the biggest buyer for large companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period to the end of last September, the UK sold drugs totaling billions to the US. This figure made up a significant portion of all goods exports in that span.
"This guarantee secures jobs, increases funding and facilitates the UK to become a global hub for medical research," a government official stated.
Specific NHS Changes
The deal involves several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to double overall health service expenditure on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must refund to the NHS to control costs will be limited at 15%. Previously, rebates were more than twenty percent.
Recent Tensions
The pact comes amid a long-running row between the sector and the British authorities over drug pricing and approval rates.
These tensions were exacerbated by claims that US patients were paying significantly more for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or scrapped, while major expansions have been directed toward US facilities.
The Science Minister acknowledged that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a share of its total funding over the past decade.
